Cell And Gene Therapy CDMO Market To Reach $27.12 Billion By 2033

Cell And Gene Therapy CDMO Market Growth & Trends

The global cell and gene therapy CDMO market size is estimated to reach USD 27.12 billion by 2033, registering to grow at a CAGR of 23.03% from 2025 to 2033 according to a new report by Grand View Research, Inc. Growing research and development activities in cell and gene therapies, heightened focus on addressing rare diseases, the expanding pipeline of innovative products, a rising need for outsourced services in this field, and continuous technological advancements in the development processes are few of the factors collectively contribute to rising demand for the market.   

Furthermore, increasing investments and funding from private and public sectors to develop novel cell and gene therapeutics is another significant factor supporting the market growth. A few of the notable examples of investments and funding in the cell and gene therapy market are mentioned below:

• In August 2021 SeQure Dx, a company specializing in gene editing diagnostics, announced a series A funding round of USD 17.5 million to develop gene therapeutics. This funding was led by Mass General Brigham Ventures and RiverVest Venture Partners, along with Casdin Capital, Digitalis Ventures, KdT Ventures, Alexandria Venture Investments, and Bold Capital Partners

• In August 2021, Eyevensys, a clinical-stage biotechnology company focusing on nonviral gene therapies for ophthalmic diseases, secured USD 12 million in a series B plus funding round

The initial phase of the COVID-19 pandemic adversely affected the market. The slowdown in overall clinical trial activity was a significant factor, primarily due to concerns about the safety of participants and staff, leading to delays and temporary suspensions. The disruption in supply chain management, particularly in transportation and logistics, posed challenges, and the uncertainty surrounding the pandemic created a general lack of demand forecast and feasibility planning. However, the market recovered through a combination of adapting to new norms, enhancing the resilience of supply chains, and implementing safety measures to navigate the challenges posed by the pandemic. Moreover, mergers and acquisition strategies adopted by the major companies have helped mitigate the negative impact of the pandemic by 2021.

 Request a free sample copy or view report summary: Cell And Gene Therapy CDMO Market Report

Cell And Gene Therapy CDMO Market Report Highlights

• The pre-clinical segment accounted for the largest share of 64.9% in 2024. The increasing pipeline of cell and gene therapeutics is one of the major factors supporting the segment’s growth.

• Based on the product type, the cell therapy segment accounted for the largest share of 42.8% in 2024. Cell therapy services are vital in advancing regenerative medicine & personalized medicine.

• The rare diseases segment is anticipated to grow at the fastest CAGR during the forecast period. The growing prevalence of several rare diseases has led to a surge in R&D activities in cell and gene therapies, thus supporting segmental growth.

• Asia Pacific is anticipated to witness the highest CAGR during the forecast time frame. The region's substantial growth is primarily attributed to the cost-effective manufacturing of cell and gene products due to lower labor and operational costs in several Asian economies.

Cell And Gene Therapy CDMO Market Segmentation

Grand View Research has segmented the global cell and gene therapy CDMO market based on phase, product, indication, and region:

Cell And Gene Therapy CDMO Phase Outlook (Revenue, USD Million, 2021 - 2033)

• Pre-clinical

• Clinical

Cell And Gene Therapy CDMO Product Outlook (Revenue, USD Million, 2021 - 2033)

• Gene Therapy

  • Ex-vivo

  • In-vivo

• Gene-Modified Cell Therapy

  • CAR T-cell therapies

  • CAR-NK cell therapy

  • TCR-T cell therapy

  • Others

• Cell Therapy

Cell And Gene Therapy CDMO Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Oncology

• Infectious Diseases

• Neurological disorders

• Rare Diseases

• Others

Cell And Gene Therapy CDMO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Oman

  • Qatar

List of Key Players in Cell And Gene Therapy CDMO Market

• Lonza

• Catalent, Inc

• Cytiva

• Samsung Biologics

• Thermo Fisher Scientific Inc.

• Novartis AG

• WuXi AppTec

• AGC Biologics

• OmniaBio

• Rentschler Biopharma SE

• Charles River Laboratories